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Testosterone is the crucial hormone in female-to-male (FtM)
transsexuals for the development of secondary sexual characteristics
of the desired gender. However, a major safety concern is whether
testosterones have a stimulatory affect on the breast that can increase
the risk of developing breast cancer. The first report of hormone
treatments of transsexuals started in the 1970s. To date, only one
breast cancer case in a FtM person has been reported in the medical
literature.1 Here we report 2 cases of breast cancers diagnosed in FtM
transsexuals.
Case 1
JK is a FtM transsexual who underwent total abdominal hysterec-
tomy and bilateral salpingo-oophorectomy (BSO) at age 46 years to
control severe endometriosis. At age 48 years, he began testosterone
injections to induce masculinization. At the same time, he began
letrozole, an aromatase inhibitor (AI), to control his residual symp-
tomatic endometriosis. He discontinued letrozole 4 years later sec-
ondary to severe joint symptoms. At age 53 years, a year after discon-
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● Testosterone is important for the development of
secondary sexual characteristics in female-to-male
(FtM) transsexuals, but it may increase breast
cancer risk. To date, only one breast cancer
case has been reported in the literature in a FtM
transsexual after 10 years of testosterone
therapy.
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Open access under CC BY-NC-ND license. tinuing letrozole, he noted a palpable mass in his left breast. He
underwent bilateral mastectomies with a left sentinel lymph node
biopsy. Histologic examination revealed invasive ductal carcinoma,
poorly differentiated, that measured 0.9 cm, grade II. All 3 nodes
were negative. The estrogen receptor (ER) expression was positive, at
90%; progesterone receptor (PR), 0%; human epidermal growth
factor receptor 2 (HER2), 3; and Ki-67, 30%. The right breast was
densely fibrotic. He had a strong family history of breast and ovarian
cancer, with a maternal aunt diagnosed with breast cancer at age 32
years and a maternal grandmother diagnosed with ovarian cancer at
age 60 years. He tested negative for BRCA mutations.
Clinical examination at the time of the initial oncology clinic visit
revealed masculinization, with facial and body hair. A hormone pro-
file was consistent with a menopausal state with high follicle-stimu-
lating hormone and luteinizing hormone, and a low estradiol level
because he had discontinued testosterone therapy before surgery. He
received 6 cycles of TCH (docetaxel [Taxotere]/carboplatin/trastu-
zumab), followed by 1 year of trastuzumab therapy. He initially
received adjuvant tamoxifen therapy but was not able to tolerate it
due to severe adverse effects. His therapy was changed to exemestane,
which he continues with tolerable joint symptoms. He restarted low-
dose testosterone cream to maintain his masculinity and is currently
free of recurrence after 2 years of follow-up.
Case 2
NO is a FtM transsexual who began supplemental testosterone at
age 21 years to induce masculinization. At age 27 years, he noted a
ice Points
● We describe 2 cases of breast cancers diagnosed in
FtM transsexuals who have been treated with supra-
physiological doses of testosterone.
● Our 2 cases demonstrate the unique issues that con-
cern the management of FtM transsexuals with breast
cancer and examine possible roles of testosterone in
the development of breast cancer.
© 2011 Elsevier Inc.
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17-9mass in his left breast. He subsequently underwent bilateral mastec-
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418tomies, with a left axillary lymph node dissection. Pathology results
revealed a 2.5-cm, poorly differentiate, invasive ductal carcinoma in
the left breast, and 1 positive lymph node of 14 examined. ER ex-
pression was 90%, PRwas 10%,HER2was 3, andKi-67was 90%.
The right breast demonstrated nonproliferative fibrocystic changes.
He has no other significant medical history. His family history was
notable for a maternal grandmother with breast cancer. He tested
negative for BRCA mutations.
He discontinued testosterone 3 days before his initial oncology
clinic visit, and, therefore, his hormone profile demonstrated follicle-
stimulating hormone, luteinizing hormone, and estradiol levels con-
sistent with amid-cycle range, with a total testosterone of 104 ng/dL.
Staging positron emission tomography showed no evidence of met-
astatic disease. He began treatment with TCH. Adjuvant hormonal
therapy with BSO with or without tamoxifen or AI was discussed
with the patient and was to begin after the completion of chemother-
apy. Due to severe depression with suicidal ideations, he resumed
testosterone therapy.
Discussion
Testosterone is an androgen found in low levels in the female
body. It is produced in the ovaries and the adrenal gland, and via
conversion of other steroid hormones. Circulating testosterone can
be converted to dihydrotestosterone (DHT) by 5-reductase or to
stradiol by the aromatase enzyme. Testosterone levels typically de-
line as women age, due to declining ovarian and adrenal function.
lthough the mechanism by which estrogens promote breast cancer
s described in the literature,2 the role of testosterone on breast tissue
s not certain. One proposed mechanism for a stimulatory effect on
he breast (or on breast cancers) is that testosterone can be aromatized
nto estrogens. Higher circulating testosterones may increase estro-
en generation within peripheral tissues, particularly the mammary
lands.
Another mechanism of testosterone’s stimulatory effect is through
he direct activation of the androgen receptors (ARs). Ligand-acti-
ated AR can regulate gene expression through binding to androgen
esponse elements located in a gene’s enhancer or promoter region.
Rs are abundant in normal mammary tissue and in the majority of
reast cancer cell lines.3,4 In addition, a significant number of tumors
hat are negative for ER and PR are positive for AR, which suggests
he independent expression of AR in human breast cancer. The pres-
nce of AR in breast cancer tumors has been associated with distinct
linical and pathological prognostic factors.5 Several studies have
xamined the effects of androgens on the growth of AR-positive
reast cancer cell lines, and results have shown stimulatory effects in
ells, regardless of their ER status.6-9 Bicalutamide, an inhibitor of
Rs, is currently in a phase II clinical trial for patients withmetastatic
reast cancer that are ER and PR negative but express AR. It is very
lausible that both testosterones and dihydrotestosterone, through
inding to ARs, can modulate breast cancer carcinogenesis, but the
recise mechanisms involved remain unknown.10
Breast cancer has been linked to elevations in endogenous testos-
terone levels in many epidemiologic studies. A pooled analysis of 9
prospective studies in postmenopausal women found a strong asso-
ciation of breast cancer risk with serum concentration of testoster-
one, the relative risk for breast cancer was 2.22 (95% confidence
Clinical Breast Cancer December 2011interval, 1.59-3.10) when comparing testosterone levels from the
highest to lowest quintile.11 The Nurses’ Health Study12 and the
large European Prospective Study into Cancer and Nutrition13
reached similar conclusions. Whether this association reflects a role
of testosterone in promotion of breast cancers or, alternatively, indi-
cates that testosterone may serve as a growth factor for an already
established tumor cannot be determined based on present data.
FtM transsexuals serve as an ideal model to examine the effects of
testosterone on breast tissue because they are treatedwith supraphysi-
ological doses of testosterone that result in serum levels in the mid-
normal male range. In FtM transsexuals receiving androgen treat-
ment, substantial amounts of circulating levels of 17ß-estradiol (E2)
are generated from peripheral aromatization of testosterone. In a
study of testosterone-treated FtM transsexuals, peak plasma E2 levels
reached 300 pmol/L, and never fell below 85 pmol/L.14
Interestingly, on clinical examination, systemic testosterone ther-
apy in FtM transsexuals usually leads to a reduction of breast size
mediated by connective tissue shrinking and local fibrosis.15-17 His-
ologic examinations of breast tissues in FtM individuals after testos-
erone therapy also showedmarked reduction of glandularmammary
land tissues and increased fibrous connective tissue.18,19 Only one
reast cancer case has been reported in the literature, in a FtM trans-
exual after 10 years of testosterone therapy.1 Similarly, our 2 pa-
tients were treated with5 years of testosterone before the develop-
ment of breast cancers. It is likely that most studies of FtM
transsexuals were too short to observe any hormone-related tu-
mors.16,20 In addition, transsexualism is rare, which may lead to
underestimation of tumors because most clinicians will only encoun-
ter single cases, which are less likely to be reported in the literature.
In addition, in a recent study that examined gene expression sig-
natures in breast tissues of 5 FtM transsexuals before and after 2 years
of intramuscular testosterone therapy, testosterone led to upregula-
tion of 243 genes that were associated with breast cancer–specific
gene expression signatures.21 The researchers concluded that testos-
terone has widespread genetic effects on breast tissue, which can lead
to the development of breast cancer.21 FtM transsexuals who request
estosterone supplements, therefore, must be made aware of the in-
reased risk arising from such treatment.
Both cases of breast cancer in our study are ER and HER2,
with low to no PR expression. In a few studies that have looked at
testosterone and breast cancer hormone receptor status, 2 have
shown high testosterone levels to be associated with increased risk of
ER breast cancer irrespective of PR status.12,22 Could these 2 pa-
ients illustrate the association of testosterone supplementation with
R breast cancer? A purported mechanism is that testosterone is
likely converted to estrogen by aromatization within tumor cells,
which would directly stimulate tumor cell proliferation.
Data on HER2 expression in relation to testosterone exposure are
limited. One study showed that the increased breast cancer risk as-
sociated with high testosterone was independent of the HER2 status
of the cancer.22 The overexpression of HER2 seen in both of our
cases suggests that testosterone can affect breast cancer by mecha-
nismsm, in addition to its conversion to estrogen, possibly through
differential interactions between estrogen and AR signaling.
Both individuals also have family histories of breast cancer but did
not have prophylactic mastectomy while receiving hormonal manip-
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Theresa Shao et alulation. The first patient had a BSO, which did not prevent the
development of breast cancer. In FtM transsexuals who have not
undergone mastectomy, clinicians should be aware of the potential
for development of breast cancer.
There are several challenges regarding the management of our
patients. First, both patients chose to remain on testosterone. Tes-
tosterone use is contraindicated in women with a history of breast
cancer, therefore, little is known about its use in this setting. Treat-
ment of women with physiological testosterone to remedy sexual
dysfunction has been an area of great interest. Most of the studies
used testosterone in addition to estrogen, thereby confounding the
assessment of breast cancer risk. In 1 large study, 814 postmeno-
pausal women with sexual dysfunction and who were not receiving
estrogen were randomized to receive a testosterone patch of either
150 or 300g/day or placebo.23 At 24 weeks, there were only 4 cases
of breast cancer in the group, but all happened in patients who
received testosterone.23 However, the short time on testosterone
therapy implies that all of these cases of breast cancer were established
before testosterone therapy was started.
The only case of breast cancer in an FtM transsexual reported in
the literature continued on low-dose testosterone, with no disease
recurrence after 5 years of follow-up.1 Although adequate androgen
replacement is necessary to preserve both patients reassigned gender
and masculinity, these benefits must be balanced against the theoret-
ical risk that androgen therapy may promote recurrence of their
breast cancers. The use of an AI may mitigate the deleterious effects
of exogenous testosterone by inhibiting aromatization. An ongoing
pilot study is evaluating the safety of 1% testosterone cream as treat-
ment for vaginal dryness and decreased libido in postmenopausal
women with early-stage breast cancer and who are receiving an AI.
The optimal hormonal management in breast cancer patients who
continue testosterone is of debate. Prophylactic oophorectomy was
suggested to patient NO because it leads to induction of artificial
menopause. Adjuvant tamoxifen is recommended for most men after
mastectomy, but there are no data regarding the role of AIs in male
breast cancer. Although the administration of AIs to patients who
continue testosterone is theoretically attractive, the efficacy of AI in
the presence of exogenous testosterones has not been studied, and it
is unclear if FtM on exogenous testosterone will have as complete
estrogen suppression with AI as do postmenopausal women.
As a compromise, Patient JK has been maintained on a low-dose
testosterone cream that provides acceptable features of masculinity.
He could not tolerate tamoxifen because of increased lower extremity
edema, vaginal discharge, and joint pain, and is currently receiving
exemestane. He has been followed-up closely with estradiol levels
remaining in the menopausal range, with no evidence of recurrent
cancer 2 years after his initial diagnosis. Patient NO likely will un-
dergo BSO and start adjuvant tamoxifen. He also will be monitored
closely, with the goal of maintaining his well-being with the lowest
possible dose of testosterone supplement.
Conclusion
Our 2 cases demonstrate the unique issues concerning the man-agement of FtM transsexuals with breast cancer, and address possibleroles of testosterone in the development of breast cancer. Although
high doses of testosterone might increase the risk of breast cancer, it
is evident that testosterone is not a single contributing hormonal
factor. To date, testosterone’s role in female physiology is not yet
fully defined, and further research is needed to determine the molec-
ular defects involved in the androgenic pathways in breast cancer.
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